Healthcare
Innovent Biologics, Inc.(IVBXF)
Live Price
Offline$9.96
+0.00% today
1Y Change
-6.00%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $134.89B
- Revenue Growth
- +34.8%
- EPS Growth
- +909.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Innovent Biologics, Inc. (IVBXF) is a Healthcare stock with a market cap of $134.89B and listed on OTC. The stock last traded around $9.96 and down 6.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +34.8%, EPS growth of +909.0%, a dividend yield of 0.0%. What stands out right now is revenue +34.8%, EPS +909.0%, free cash flow 0.0% with operating margin 11.3% and ROIC 4.7%. Valuation already assumes a fairly strong business story at P/E 87.5 and price/sales 10.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IVBXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+34.8% vs +7.6% peer median
Operating Margin
Below sector median
+11.3% vs +19.4% peer median
P/E
Above sector median
87.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 26, 2026 with an EPS surprise of -108.3% and a revenue surprise of +2.8%.
The operating story is still moving forward
Revenue is running at +34.8% and EPS at +909.0%, with operating margin around 11.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 26, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 26, 2026 | -108.3% | +0.0% | +10.4% | -3.1% |
2025 Aug 27, 2025 | +173.3% | +0.0% | +14.7% | +1.2% |
2025 Mar 26, 2025 | +179.4% | -2.3% | -1.9% | +10.2% |
Benchmark Edge
IVBXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IVBXF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IVBXF Max Drawdown
-33.87%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IVBXF and SPY.
Company Overview
Innovent Biologics, Inc.
Other OTC
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
- Leadership
- De-Chao Yu
- IPO Date
- Sep 4, 2019
- Employees
- 5.7k
- Street Address
- 168 Dongping Street
- Mailing
- Suzhou, 215123
- Region
- Suzhou, CN
- Reporting Currency
- USD
- Investor Line
- 86 512 6956 6088
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 87.5
- EV/EBITDA
- 74.9
- Price/Sales
- 10.4
- Price/Book
- 3.7
Growth
- Revenue
- +34.8%
- EPS
- +909.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 82.3%
- Operating Margin
- 11.3%
- Net Margin
- 6.3%
- ROE
- 4.8%
- ROIC
- 4.7%
Balance Sheet
- Debt/Equity
- 0.15
- Current Ratio
- 2.62
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.